Asia Tides 2012
29 Feb 2012 - 01 Mar 2012 - Tokyo, Japan
There is no doubt that the pharmaceutical industry continues investing large amounts in peptide and oligonucleotide drug development AsiaTIDES is a unique opportunity to update your knowledge of the latest research and manufacturing technologies for oligonucleotide- and peptide-based therapeutics and access this rapidly growing market area. Hear the latest reports from around the world - a program agenda not available at any other event in Japan - at a convenient forum in Tokyo Meet new collaborators, gain new potential future partners to help fill your portfolio and pipeline, and find out the up-to-the-minute status of delivery technologies that can help ensure robust market share for these therapeutics.
AsiaTIDES continues to be the premier forum to get a comprehensive update, meet key players and increase your knowledge of the oligonucleotide- and peptide-based therapeutics fields.
The faculty list for the 2012 program is the strongest yet, with more representation from big pharma than ever before. Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape. Plus hear from Isis, Novo Nordisk, Ipsen, Quark, Alnylam, Santaris, Tekmira and a host of other important companies you need to follow to stay abreast of this field.